Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing

JAMA Oncology - United States
doi 10.1001/jamaoncol.2017.4021
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Medical Association (AMA)

Related search

Prevalence of KRAS, BRAF, PI3K and EGFR Mutations Among Asian Patients With Metastatic Colorectal Cancer

Oncology Letters
Cancer ResearchOncology
2015English

T Cell-Engaging BiTE Antibodies Specific for EGFR Potently Eliminate KRAS- And BRAF-mutated Colorectal Cancer Cells

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2010English

FDA-Approved Biosimilar Insulin

Journal of diabetes science and technology
Internal MedicineEndocrinologyBioengineeringBiomedical EngineeringMetabolismDiabetes
2014English

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma

Cancers
Cancer ResearchOncology
2019English

Repurposing FDA-approved Drugs for Anti-Aging Therapies

Biogerontology
AgingGerontologyGeriatrics
2016English

Validation of KRAS Testing for Anti-Egfr Therapeutic Decisions for Patients With Metastatic Colorectal Carcinoma

Archives of Pathology and Laboratory Medicine
MedicineForensic MedicinePathologyMedical Laboratory Technology
2012English

Clinical Utility of KRAS and BRAF Mutations in a Cohort of Patients With Colorectal Neoplasms Submitted for Microsatellite Instability Testing

Clinical Colorectal Cancer
OncologyGastroenterology
2013English

From the FDA: Heart Pump Approved

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1994English

From the FDA: Epilepsy Drug Approved

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1994English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy